Is severe confluent mucositis precisely qualified dose-limiting for altered radiotherapy for H&N cancer?

被引：0
|
作者：
Maciejewski, B. [1 ]
机构：
[1] MSC Inst Branch GL, Ctr Canc, Gliwice, Poland
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2007年 / 69卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2007.07.1631
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2454
引用
收藏
页码：S454 / S454
页数：1
相关论文
共 50 条
  • [41] Automatic CT-To-CT Contour Segmentation Using Deformable Image Registration Software for Head and Neck (H&N) Cancer Adaptive Radiotherapy
    Kumarasiri, A.
    Kim, J.
    Liu, C.
    Siddiqui, F.
    Chetty, I.
    MEDICAL PHYSICS, 2013, 40 (06)
  • [42] AI-Seg: An Artificial Intelligence (AI)-Based Automatic Organs at Risk (OAR) Contouring Platform for Head and Neck Cancer (H&N) Radiotherapy
    Wu, J.
    Lynch, P.
    Shah, J.
    Lu, W.
    Gu, X.
    MEDICAL PHYSICS, 2019, 46 (06) : E122 - E122
  • [43] Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
    Osei-Fofie, D.
    Dimitriu, M.
    Landers, G.
    Wetter, J.
    Kraus, P. A.
    Lategan, A.
    Sonis, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1103 - S1103
  • [44] Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head and neck (H&N) cancer.
    Osei-Fofie, Daniel
    Wetter, Julie
    Landers, Greg A.
    Kraus, Peter Alfred
    Sukumaran, Shawgi
    Mun, Hui
    Stein, Brian N.
    Bray, Victoria Jane
    Framroze, Bomi
    Gelfand, Jeffrey
    Song, Paul Y.
    Lategan, Andries
    Dimitriu, Mikaela
    Sonis, Stephen T.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
    Osei-Fofie, D.
    Landers, G.
    Wetter, J. A.
    Kraus, P.
    Sukumaran, S.
    Mun, H.
    Stein, B.
    Bray, V. J.
    Connell, C. A.
    Framroze, B.
    Gelfand, J.
    Lategan, A.
    Song, P.
    Dimitriu, M.
    Sonis, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1058 - S1059
  • [46] 64Cu-atsm pet/ct and 18f-fdg pet/ct in patients with h&n cancer candidate to radiotherapy: preliminary results.
    Nanni, C.
    Grassi, I.
    Cicoria, G.
    Ambrosini, V.
    Cecconi, A.
    Castellucci, P.
    Montini, G.
    Allegri, V.
    Pettinato, C.
    Barbieri, E.
    Fanti, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S408 - S409
  • [47] Correlation of maximum dose in PTV and the need for in-hospital supportive care during radiotherapy for H and N cancer patients
    Verma, Kamal
    Kumawat, Naveen
    Goel, Sandeep
    Pande, Subodh Chandra
    Sharma, Ajendra Pratap
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2020, 16 (03) : 530 - 533
  • [48] Toward Adaptive Volumetric Modulated Arc Therapy (AVMAT) for Head and Neck (H&N) Cancer: Dose Reconstruction Using On-Treatment CBCT and Dynamic Log-Files
    Qian, J.
    Lee, K.
    Chu, K.
    Le, Q.
    Xing, L.
    MEDICAL PHYSICS, 2010, 37 (06)
  • [49] Hyperfractionated radiotherapy (Hfx RT) with or without concurrent low-dose daily cisplatin (CDDP) in locally advanced unresectable squamous cell carcinoma of the head and neck (SCC H&N). A prospective randomized trial
    Jeremic, B
    Shibamoto, Y
    Milicic, B
    Nikolic, N
    Dagovic, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S163 - S163
  • [50] To improve nutrition of head and neck (H&N) cancer patients receiving radical radiotherapy (RT) in an outpatient setting by establishing a nasogastric (NG) feeding service to reduce lengthy inpatient stays and improve patient outcomes
    McCloskey, P.
    Duffy, C.
    Brown, K.
    Irwin, A.
    Faloon, S. -J.
    CLINICAL ONCOLOGY, 2019, 31 : E7 - E7
12345